Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients

Coronary Artery Disease

Volumn 20, Issue 4, 2009, Pages 267-273

  Chiang, Kuang Hsing ^a   Huang, Po Hsun ^a,b,c   Huang, Shao Sung ^a   Wu, Tao Cheng ^a,c   Chen, Jaw Wen ^a,c,d   Lin, Shing Jong ^a,b,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Institute of Clinical Medicine   (Taiwan)

^c Cardiovascular Research Center   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cardiovascular events; Endothelial function; Soluble receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVASCULARIZATION; THROMBOSIS; VASODILATATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DISEASE-FREE SURVIVAL; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VASODILATION; YOUNG ADULT;

EID: 67649668763     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32832c459c     Document Type: Article

References (37)

1. Hudson Bl, Schmidt AM. RAGE: a novel target for drug intervention in diabetic vascular disease. Pharm Res 2004; 21:1079-1086.
2. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006; 91:4628-4634.
3. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/ calgranulin polypeptides. Cell 1999; 97:889-901.
4. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46:223-234.
5. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93:1159-1169.
6. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274:31740-31749.
7. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106:2827-2835.
8. Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 2009; 19:129-134.
9. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vase Biol 2005; 25:1032-1037.
10. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006; 13:1971-1978.
11. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vase Biol 2003; 23:168-175.
12. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109:27-32.
13. Huang PH, Chen JW, Wu TC, Ding YA, Lin SJ. Combined use of endothelial function and high-sensitive C-reactive protein in predicting cardiovascular events in patients with suspected coronary artery disease. C//n Cardiol 2007; 30:135-140.
14. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-1197.
15. Huang PH, Leu HB, Chen JW, Wu TC, Lu TM, Ding YA, et al. Comparison of endothelial vasodilator function, inflammatory markers, and N-terminal pro-brain natriuretic peptide in patients with or without chronotropic incompetence to exercise test. Heart 2006; 92:609-614.
16. Huang PH, Chen LC, Leu HB, Ding PY, Chen JW, Wu TC, et al. Enhanced coronary calcification determined by electron beam CT is strongly related to endothelial dysfunction in patients with suspected coronary artery disease. Cfiesf 2005; 128:810-815.
17. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994; 94:110-117.
18. Koch KM. Dialysis-related amyloidosis. Kidney Int 1992; 41:1416-1429.
19. Malherbe P, Richards JG, Gaillard H, Thompson A, Diener C, Schuler A, et al. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res 1999; 71:159-170.
20. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370:1097-1109.
21. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111:959-972.
22. Fathi R, Haluska B, Isbel N, Short L, Marwick TH. The relative importance of vascular structure and function in predicting cardiovascular events. J Am Coll Cardiol 2004; 43:616-623.
23. Frick M, Suessenbacher A, Alber HF, Dichtl W, Ulmer H, Pachinger O, et al. Prognostic value of brachial artery endothelial function and wall thickness. J Am Coll Cardiol 2005; 46:1006-1010.
24. Moens AL, Goovaerts I, Claeys MJ, Vrints CJ. Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool? Chest 2005; 127:2254-2263.
25. Schafer Al. Vascular endothelium: in defense of blood fluidity. J Clin Invest 1997; 99:1143-1144.
26. Huang PH, Leu HB, Chen JW, Wu TC, Ding YA, Lin SJ. Decreased heparin cofactor II activity is associated with endothelial dysfunction and modestly predicts cardiovascular events in patients with suspected coronary artery disease. Int J Cardiol 2007; 114:152-158.
27. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemia humans. J Clin Invest 1990; 86:228-234.
28. Henry RM, Ferreira I, Kostense PJ, Dekker JM, Nijpels G, Heine PJ, et al. Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not: the Hoorn Study. Atherosclerosis 2004; 174:49-56.
29. Ward NC, Croft KD, Hodgson J, Rich L, Beilin U, Puddey IB. Brachial artery vasomotor function is inversely associated with 24-h ambulatory blood pressure. J Hypertens 2004; 22:967-972.
30. Tsuchiya M, Asada A, Kasahara E, Sato EF, Shindo M, Inoue M. Smoking a single cigarette rapidly reduces combined concentrations of nitrate and nitrite and concentrations of antioxidants in plasma. Circulation 2002; 105:1155-1157.
31. Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002; 25:1055-1059.
32. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101:1899-1906.
33. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol 1995; 26:1235-1241.
34. Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol 2003; 42:1037-1043.
35. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, et al. Serum levels of sRAGE, the soluble form of-reoeptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007; 13:185-189.
36. Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with diabetes. Microvasc Res 2008; 76:52-56.
37. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007; 23:368-371.